On August 3, 2020 Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR, reported the appointment of Peter G. Traber, MD, to the position of Chief Medical Officer (Press release, Selecta Biosciences, AUG 3, 2020, View Source [SID1234562700]). Dr. Traber has been serving in the same position in an interim capacity, and joins the Company full-time, effective August 1, 2020.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Since becoming part of our organization, Peter has brought a wealth of expertise from his experience in large pharma, biotech, and academia that has substantially strengthened our clinical development capabilities, and we are extremely pleased that he will be joining us full-time as Chief Medical Officer," said Carsten Brunn, Ph.D., President and CEO of Selecta. "We’re confident that he will play a critical role in elevating the strength of our science and translating it clinically, as we explore new applications for ImmTOR in biologics, gene therapy, and immunotherapies for autoimmune diseases."
"I am proud to be part of an organization that is pioneering innovations that may advance the treatment of a number of challenging diseases with unmet needs," said Dr. Traber. "Selecta has the capabilities and scientific acumen to become the undisputed leader in targeted and specific immune tolerance, and I’m excited to help advance ImmTOR and explore its role in driving innovation that will ultimately help patients."
As Chief Medical Officer, Dr. Traber will oversee medical affairs, program management, and all aspects of clinical development and strategy, as well as provide scientific and clinical guidance for potential business development initiatives. He is the founder and president of PGT Life Sciences Consulting, a biopharmaceutical consultancy for which he provides drug development strategy, clinical trial design, and scientific oversight for a broad range of companies. In a previous role, Dr. Traber was the President, Chief Executive Officer, and Chief Medical Officer of Galectin Therapeutics. During his tenure, he successfully built a full drug development team and created the strategy to progress its lead compound forward in multiple indications, including a phase 3-ready program in NASH cirrhosis. Prior to Galectin, he served as the Chief Medical Officer and Senior Vice President, Clinical Development & Medical Affairs at GSK. Previously, he served as the President and CEO of the Baylor College of Medicine, and Chairman of Medicine and CEO of the University of Pennsylvania Health System. His experience also includes managing an academic research laboratory, serving on the editorial boards of medical journals, and he has authored more than 100 research articles, reviews, and book chapters. He received his medical degree from Wayne State University School of Medicine, holds a Bachelor of Science in Chemical Engineering from the University of Michigan, and earned a certificate in Medical Leadership from Wharton Business School. He is currently an Adjunct Professor of Medicine at the University of Pennsylvania and serves on the board of Caladrius Biosciences.